Age-related macular degeneration before and after the era of anti-VEGF drugs
NIH-funded study of Avastin and Lucentis examines their effects at five years. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 3, 2016 Category: American Health Source Type: news
Many With Wet AMD Need Ranibizumab Retreatment Even After Year-Long PauseMany With Wet AMD Need Ranibizumab Retreatment Even After Year-Long Pause
Retreatment with ranibizumab is necessary for up to a third of neovascular age-related macular degeneration (AMD) patients who are treatment-free for one year, new research shows. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 27, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Delayed Visual Improvements in AMD Continue With Ranibizumab TreatmentDelayed Visual Improvements in AMD Continue With Ranibizumab Treatment
Visual improvements in patients with neovascular age-related macular degeneration (AMD) treated with ranibizumab continue after macular edema resolves, researchers report. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 30, 2016 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Aflibercept for Macular Edema Secondary to Central RVOAflibercept for Macular Edema Secondary to Central RVO
Aflibercept may be an effective therapeutic option for macular edema due to central retinal vein occlusion that did not respond to treatment with bevacizumab or ranibizumab. Eye (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2016 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Aflibercept Best in Diabetics With Bad Baseline Vision? Aflibercept Best in Diabetics With Bad Baseline Vision?
Final results from a trial comparing aflibercept, bevacizumab, and ranibizumab in diabetic macular edema confirm all three drugs are similar, but aflibercept is best in those with worse baseline vision, says lead researcher. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 1, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
DME Drugs Equally Effective at 2 Years
(MedPage Today) -- But more adverse events seen with Lucentis versus Eylea (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 29, 2016 Category: Cardiology Source Type: news
Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss
NIH-funded clinical trial shows Eylea, Avastin, and Lucentis perform similarly when vision loss is mild. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 29, 2016 Category: American Health Source Type: news
Study Compares Drugs for Common Diabetic Eye Disease
MONDAY, Feb. 29, 2016 -- People with diabetes are at risk for blurred vision or even a loss of vision from a condition called macular edema.
Three drugs for the disease -- Avastin, Eylea and Lucentis -- vary widely in price, but new research... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 29, 2016 Category: Journals (General) Source Type: news
Long-term Outcomes of Ranibizumab for Neovascular AMDLong-term Outcomes of Ranibizumab for Neovascular AMD
What is the long-term outlook for patients receiving ranibizumab injections for previously untreated neovascular AMD? The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 25, 2016 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Ranibizumab for the Treatment of Wet AMDRanibizumab for the Treatment of Wet AMD
Ranibizumab for wet AMD has shown success in clinical trials, but are those same results achieved in real-world clinical practice? Eye (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 25, 2016 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news
Eylea Outperforms Avastin for Diabetic Macular Edema with Moderate or Worse Vision Loss
A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), but only among participants starting treatment with 20/50 or worse vision. Gains after two years were about the same for Eylea and Lucentis (ranibizumab), contrary to year-one results from the study, which showed Eylea with a clear advantage.
Language
English (Source: News from NEI)
Source: News from NEI - February 25, 2016 Category: Opthalmology Authors: Jason Source Type: news
Diabetic Vision Loss Medication May Promote Return to DrivingDiabetic Vision Loss Medication May Promote Return to Driving
After a year of treatment with the drug ranibizumab (Lucentis), some people with vision loss due to diabetes regain their confidence to drive and have vision good enough to do so, according to a new study. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - November 30, 2015 Category: Opthalmology Tags: Diabetes & Endocrinology News Source Type: news
Diabetic vision loss medication may promote return to driving
(Reuters Health) - After a year of treatment with the drug ranibizumab (Lucentis), some people with vision loss due to diabetes regain their confidence to drive and have vision good enough to do so, according to a new study. (Source: Reuters: Health)
Source: Reuters: Health - November 26, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
New treatment options, better hope of preventing vision loss from diabetes
This National Diabetes Month, there is some good news for people with eye complications from diabetes. A network of researchers has found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes. The researchers say this is the first major advance in therapy in 40 years. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 19, 2015 Category: Science Source Type: news
New Treatment Options, Better Hope of Preventing Vision Loss from Diabetes
This National Diabetes Month, there is some good news for people with eye complications from diabetes. Earlier this month, a network of researchers supported by the National Eye Institute (NEI) found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes. The researchers, part of the Diabetic Retinopathy Clinical Research Network, say this is the first major advance in therapy in 40 years. (Source: News from NEI)
Source: News from NEI - November 19, 2015 Category: Opthalmology Authors: Jason Source Type: news
